Noninfectious pulmonary complications of human immunodeficiency virus infection

American Journal of the Medical Sciences

Volumn 348, Issue 6, 2014, Pages 502-511

  Staitieh, Bashar ^a   Guidot, David M ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

HIV; Interstitial lung disease; Lung; Lung cancer; Pulmonary hypertension

Indexed keywords

ANTIRETROVIRUS AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; EFAVIRENZ; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; VIRUS PROTEIN; WARFARIN;

BACTERIAL PNEUMONIA; BRONCHIECTASIS; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIURETIC THERAPY; EMPHYSEMA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INTERNATIONAL NORMALIZED RATIO; INTERSTITIAL LUNG DISEASE; LUNG BLOOD VESSEL; LUNG CANCER; LUNG DISEASE; LUNG PARENCHYMA; NONHUMAN; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; REVIEW; ASTHMA; COMPLICATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HYPERTENSION, PULMONARY; LUNG DISEASES; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; LYMPHOMA, NON-HODGKIN; PULMONARY EMPHYSEMA; SARCOMA, KAPOSI;

ASTHMA; BRONCHIECTASIS; HIV INFECTIONS; HIV-1; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; LYMPHOMA, NON-HODGKIN; PULMONARY EMPHYSEMA; SARCOMA, KAPOSI;

EID: 84922395111     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0000000000000318     Document Type: Review

References (118)

1. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007;146:87-95.
2. Akinbami LJ, Moorman JE, Bailey C, et al. Trends in asthma prevalence, health care use, and mortality in the United States, 2001- 2010. NCHS Data Brief No. 94 May 2012;1-8.
3. Poirier CD, Inhaber N, Lalonde RG, et al. Prevalence of bronchial hyperresponsiveness among HIV-infected men. Am J Respir Crit Care Med 2001;164:542-5.
4. Wallace JM, Stone GS, Browdy BL, et al. Nonspecific airway hyperresponsiveness in HIV disease. Pulmonary Complications of HIV Infection Study Group. Chest 1997;111:121-7.
5. Crothers K, Huang L, Goulet JL, et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med 2011;183:388-95.
6. Gingo MR, Wenzel SE, Steele C, et al. Asthma diagnosis and airway bronchodilator response in HIV-infected patients. J Allergy Clin Immunol 2012;129:708-14.e8.
7. Diaz PT, Clanton TL, Pacht ER. Emphysema-like pulmonary disease associated with human immunodeficiency virus infection. Ann Intern Med 1992;116:124-8.
8. Crothers K, Butt AA, Gibert CL, et al. Increased COPD among HIV-positive compared to HIV-negative veterans. Chest 2006;130: 1326-33.
9. Hirani A, Cavallazzi R, Vasu T, et al. Prevalence of obstructive lung disease in HIV population: A cross sectional study. Respir Med 2011; 105:1655-61.
10. Sheikh S, Madiraju K, Steiner P, et al. Bronchiectasis in pediatric AIDS. Chest 1997;112:1202-7.
11. Holmes AH, Trotman-Dickenson B, Edwards A, et al. Bronchiectasis in HIV disease. Q J Med 1992;85:875-82.
12. Verghese A, al-Samman M, Nabhan D, et al. Bacterial bronchitis and bronchiectasis in human immunodeficiency virus infection. Arch Intern Med 1994;154:2086-91.
13. Holmes AH, Pelton S, Steinbach S, et al. HIV related bronchiectasis. Thorax 1995;50:1227.
14. Cocchi F, DeVico AL, Garzino-Demo A, et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270:1811-5.
15. Muro M, Marín L, Torio A, et al. CCL5/RANTES chemokine gene promoter polymorphisms are not associated with atopic and nonatopic asthma in a Spanish population. Int J Immunogenet 2008;35:19-23.
16. Tesoriero JM, Gieryic SM, Carrascal A, et al. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav 2010;14:824-35.
17. Drummond MB, Kirk GD, Astemborski J, et al. Association between obstructive lung disease and markers of HIV infection in a high-risk cohort. Thorax 2012;67:309-14.
18. Lassiter C, Fan X, Joshi PC, et al. HIV-1 transgene expression in rats causes oxidant stress and alveolar epithelial barrier dysfunction. AIDS Res Ther 2009;6:1.
19. Joshi PC, Raynor R, Fan X, et al. HIV-1-transgene expression in rats decreases alveolar macrophage zinc levels and phagocytosis. Am J Respir Cell Mol Biol 2008;39:218-26.
20. Schulz L, Nagaraja HN, Rague N, et al. Respiratory muscle dysfunction associated with human immunodeficiency virus infection. Am J Respir Crit Care Med 1997;155:1080-4.
21. Kling HM, Shipley TW, Patil SP, et al. Relationship of Pneumocystis jiroveci humoral immunity to prevention of colonization and chronic obstructive pulmonary disease in a primate model of HIV infection. Infect Immun 2010;78:4320-30.
22. Shipley TW, Kling HM, Morris A, et al. Persistent pneumocystis colonization leads to the development of chronic obstructive pulmonary disease in a nonhuman primate model of AIDS. J Infect Dis 2010; 202:302-12.
23. Kaner RJ, Santiago F, Crystal RG. Up-regulation of alveolar macrophage matrix metalloproteinases in HIV1(+) smokers with early emphysema. J Leukoc Biol 2009;86:913-22.
24. Boutten A, Goven D, Boczkowski J, et al. Oxidative stress targets in pulmonary emphysema: focus on the Nrf2 pathway. Expert Opin Ther Targets 2010;14:329-46.
25. Fan X, Staitieh BS, Jensen JS, et al. Activating the Nrf2-mediated antioxidant response element restores barrier function in the alveolar epithelium of HIV-1 transgenic rats. Am J Physiol Lung Cell Mol Physiol 2013;305:L267-L77.
26. Nakamura H, Masutani H, Yodoi J. Redox imbalance and its control in HIV infection. Antioxid Redox Signal 2002;4:455-64.
27. Amorosa JK, Miller RW, Laraya-Cuasay L, et al. Bronchiectasis in children with lymphocytic interstitial pneumonia and acquired immune deficiency syndrome. Plain film and CT observations. Pediatr Radiol 1992;22:603-6; discussion 606-7.
28. Masekela R, Anderson R, Moodley T, et al. HIV-related bronchiectasis in children: An emerging spectre in high tuberculosis burden areas. Int J Tuberc Lung Dis 2012;16:114-9.
29. Rosen MJ, Lou Y, Kvale PA, et al. Pulmonary function tests in HIVinfected patients without AIDS. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1995;152:738-45.
30. Mitchell DM, Fleming J, Pinching AJ, et al. Pulmonary function in human immunodeficiency virus infection. A prospective 18-month study of serial lung function in 474 patients. Am Rev Respir Dis 1992;146:745-51.
31. Diaz PT, King MA, Pacht ER, et al. The pathophysiology of pulmonary diffusion impairment in human immunodeficiency virus infection. Am J Respir Crit Care Med 1999;160:272-7.
32. Gingo MR, George MP, Kessinger CJ, et al. Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era. Am J Respir Crit Care Med 2010;182:790-6.
33. George MP, Kannass M, Huang L, et al. Respiratory symptoms and airway obstruction in HIV-infected subjects in the HAART era. PLoS One 2009;4:e6328.
34. Kristoffersen US, Lebech AM, Mortensen J, et al. Changes in lung function of HIV-infected patients: A 4.5-year follow-up study. Clin Physiol Funct Imaging 2012;32:288-95.
35. Cui Q, Carruthers S, McIvor A, et al. Effect of smoking on lung function, respiratory symptoms and respiratory diseases amongst HIV-positive subjects: A cross-sectional study. AIDS Res Ther 2010;7:6.
36. Helleberg M, Afzal S, Kronborg G, et al. Mortality attributable to smoking among HIV-1-infected individuals: A nationwide, populationbased cohort study. Clin Infect Dis 2013;56:727-34.
37. Kaviani N, Bukberg P, Manessis A, et al. Iatrogenic osteoporosis, bilateral HIP osteonecrosis, and secondary adrenal suppression in an HIV-infected man receiving inhaled corticosteroids and ritonavir-boosted highly active antiretroviral therapy. Endocr Pract 2011;17:74-8.
38. Kedem E, Shahar E, Hassoun G, et al. Iatrogenic Cushing's syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient. J Asthma 2010;47:830-1.
39. Strimlan CV, Rosenow EC III, Weiland LH, et al. Lymphocytic interstitial pneumonitis. Review of 13 cases. Ann Intern Med 1978;88: 616-21.
40. Itescu S, Brancato LJ, Buxbaum J, et al. A diffuse infiltrative CD8 lymphocytosis syndrome in human immunodeficiency virus (HIV) infection: A host immune response associated with HLA-DR5. Ann Intern Med 1990;112:3-10.
41. Semenzato G. Immunology of interstitial lung diseases: cellular events taking place in the lung of sarcoidosis, hypersensitivity pneumonitis and HIV infection. Eur Respir J 1991;4:94-102.
42. Scarborough M, Lishman S, Shaw P, et al. Lymphocytic interstitial pneumonitis in an HIV-infected adult: response to antiretroviral therapy. Int J STD AIDS 2000;11:119-22.
43. Bhoopat L, Rangkakulnuwat S, Okonogi R, et al. Cell reservoirs of the Epstein-Barr virus in biopsy-proven lymphocytic interstitial pneumonitis in HIV-1 subtype E infected children: identification by combined in situ hybridization and immunohistochemistry. Appl Immunohistochem Mol Morphol 2010;18:212-8.
44. Jouveshomme S, Couderc LJ, Ferchal F, et al. Lymphocytic alveolitis after primary HIV infection with CMV coinfection. Chest 1997; 112:1127-8.
45. Setoguchi Y, Takahashi S, Nukiwa T, et al. Detection of human Tcell lymphotropic virus type I-related antibodies in patients with lymphocytic interstitial pneumonia. Am Rev Respir Dis 1991;144:1361-5.
46. Trevenzoli M, Cattelan AM, Marino F, et al. Sarcoidosis and HIV infection: A case report and a review of the literature. Postgrad Med J 2003;79:535-8.
47. Papadaki TG, Kafkala C, Zacharopoulos IP, et al. Conjunctival non-caseating granulomas in a human immunodeficiency virus (HIV) positive patient attributed to sarcoidosis. Ocul Immunol Inflamm 2006;14:309-11.
48. Cheng VC, Yuen KY, Chan WM, et al. Immunorestitution disease involving the innate and adaptive response. Clin Infect Dis 2000;30: 882-92.
49. Shelburne SA III, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002;81:213-27.
50. Almeida FA Jr, Sager JS, Eiger G. Coexistent sarcoidosis and HIV infection: An immunological paradox? J Infect 2006;52:195-201.
51. Mori S, Polatino S, Estrada YMRM. Pneumocystis-associated organizing pneumonia as a manifestation of immune reconstitution inflammatory syndrome in an HIV-infected individual with a normal CD4+ T-cell count following antiretroviral therapy. Int J STD AIDS 2009;20:662-5.
52. Godoy MC, Silva CI, Ellis J, et al. Organizing pneumonia as a manifestation of Pneumocystis jiroveci immune reconstitution syndrome in HIVpositive patients: report of 2 cases. J Thorac Imaging 2008;23:39-43.
53. Behrens GM, Stoll M, Schmidt RE. Pulmonary hypersensitivity reaction induced by efavirenz. Lancet 2001;357:1503-4.
54. Denton AS, Simpson JK, Hallam M, et al. Effects on pulmonary function of two regimens of chemotherapy for AIDS related Kaposi's sarcoma. Clin Oncol (R Coll Radiol) 1996;8:48-50.
55. Kazi S, Cohen PR, Williams F, et al. The diffuse infiltrative lymphocytosis syndrome. Clinical and immunogenetic features in 35 patients. AIDS 1996;10:385-91.
56. Kim KK, Factor SM. Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome. Hum Pathol 1987;18:1293-6.
57. Speich R, Jenni R, Opravil M, et al. Primary pulmonary hypertension in HIV infection. Chest 1991;100:1268-71.
58. Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008;177:108-13.
59. Reinsch N, Buhr C, Krings P, et al. Effect of gender and highly active antiretroviral therapy on HIV-related pulmonary arterial hypertension: results of the HIV-HEART Study. HIV Med 2008;9:550-6.
60. Isasti G, Moreno T, Perez I, et al. High prevalence of pulmonary arterial hypertension in a cohort of asymptomatic HIV-infected patients. AIDS Res Hum Retroviruses 2013;29:231-4.
61. Quezada M, Martin-Carbonero L, Soriano V, et al. Prevalence and risk factors associated with pulmonary hypertension in HIV-infected patients on regular follow-up. AIDS 2012;26:1387-92.
62. Selby VN, Scherzer R, Barnett CF, et al. Doppler echocardiography does not accurately estimate pulmonary artery systolic pressure in HIV-infected patients. AIDS 2012;26:1967-9.
63. Opravil M, Pechere M, Speich R, et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997;155:990-5.
64. Degano B, Guillaume M, Savale L, et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS 2010;24:67-75.
65. Kanmogne GD, Primeaux C, Grammas P. Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem Biophys Res Commun 2005;333: 1107-15.
66. Marecki JC, Cool CD, Parr JE, et al. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. Am J Respir Crit Care Med 2006;174:437-45.
67. Caldwell RL, Gadipatti R, Lane KB, et al. HIV-1 TAT represses transcription of the bone morphogenic protein receptor-2 in U937 monocytic cells. J Leukoc Biol 2006;79:192-201.
68. Dalvi P, O'Brien-Ladner A, Dhillon NK. Downregulation of bone morphogenetic protein receptor axis during HIV-1 and cocainemediated pulmonary smooth muscle hyperplasia: implications for HIV-related pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2013;33:2585-95.
69. Porter KM, Walp ER, Elms SC, et al. Human immunodeficiency virus-1 transgene expression increases pulmonary vascular resistance and exacerbates hypoxia-induced pulmonary hypertension development. Pulm Circ 2013;3:58-67.
70. Mermis J, Gu H, Xue B, et al. Hypoxia-inducible factor-1 alpha/platelet derived growth factor axis in HIV-associated pulmonary vascular remodeling. Respir Res 2011;12:103.
71. Cool CD, Rai PR, Yeager ME, et al. Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med 2003;349: 1113-22.
72. Hsue PY, Deeks SG, Farah HH, et al. Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension. AIDS 2008;22:825-33.
73. Valmary S, Dorfmuller P, Montani D, et al. Human gammaherpesviruses Epstein-Barr virus and human herpesvirus-8 are not detected in the lungs of patients with severe pulmonary arterial hypertension. Chest 2011;139:1310-6.
74. Henke-Gendo C, Mengel M, Hoeper MM, et al. Absence of Kaposi's sarcoma-associated herpesvirus in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2005;172:1581-5.
75. Morris A, Gingo MR, George MP, et al. Cardiopulmonary function in individuals with HIV infection in the antiretroviral therapy era. AIDS 2012;26:731-40.
76. Spikes L, Dalvi P, Tawfik O, et al. Enhanced pulmonary arteriopathy in simian immunodeficiency virus-infected macaques exposed to morphine. Am J Respir Crit Care Med 2012;185:1235-43.
77. Janda S, Quon BS, Swiston J. HIV and pulmonary arterial hypertension: A systematic review. HIV Med 2010;11:620-34.
78. Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009;179:615-21.
79. Gary-Bobo G, Houssaini A, Amsellem V, et al. Effects of HIV protease inhibitors on progression of monocrotaline- and hypoxiainduced pulmonary hypertension in rats. Circulation 2010;122: 1937-47.
80. Zuber JP, Calmy A, Evison JM, et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 2004;38:1178-85.
81. Chinello P, Cicalini S, Pichini S, et al. Sildenafil plasma concentrations in two HIV patients with pulmonary hypertension treated with ritonavir-boosted protease inhibitors. Curr HIV Res 2012;10:162-4.
82. Schumacher YO, Zdebik A, Huonker M, et al. Sildenafil in HIVrelated pulmonary hypertension. AIDS 2001;15:1747-8.
83. Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;170:1212-7.
84. Degano B, Yaici A, Le Pavec J, et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J 2009;33:92-8.
85. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebocontrolled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010-9.
86. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000;162:1846-50.
87. Cicalini S, Chinello P, Grilli E, et al. Treatment and outcome of pulmonary arterial hypertension in HIV-infected patients: A review of the literature. Curr HIV Res 2009;7:589-96.
88. Gritz ER, Vidrine DJ, Lazev AB, et al. Smoking behavior in a lowincome multiethnic HIV/AIDS population. Nicotine Tob Res 2004;6:71-7.
89. Marshall MM, Kirk GD, Caporaso NE, et al. Tobacco use and nicotine dependence among HIV-infected and uninfected injection drug users. Addict Behav 2011;36:61-7.
90. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008;148:728-36.
91. Sigel K, Wisnivesky J, Gordon K, et al. HIV as an independent risk factor for incident lung cancer. AIDS 2012;26:1017-25.
92. Palmieri C, Dhillon T, Thirlwell C, et al. Pulmonary Kaposi sarcoma in the era of highly active antiretroviral therapy. HIV Med 2006;7:291-3.
93. Bower M, Nelson M, Young AM, et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol 2005;23:5224-8.
94. Leidner RS, Aboulafia DM. Recrudescent Kaposi's sarcoma after initiation of HAART: A manifestation of immune reconstitution syndrome. AIDS Patient Care STDS 2005;19:635-44.
95. Stover KR, Molitorisz S, Swiatlo E, et al. A fatal case of Kaposi sarcoma due to immune reconstitution inflammatory syndrome. Am J Med Sci 2012;343:421-5.
96. Ensoli B, Gallo RC. AIDS-associated Kaposi's sarcoma: A new perspective of its pathogenesis and treatment. Proc Assoc Am Physicians 1995;107:8-18.
97. Ensoli B, Gendelman R, Markham P, et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 1994;371:674-80.
98. Sarid R, Sato T, Bohenzky RA, et al. Kaposi's sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. Nat Med 1997;3:293-8.
99. Cadranel J, Naccache J, Wislez M, et al. Pulmonary malignancies in the immunocompromised patient. Respiration 1999;66:289-309.
100. Huhn GD, Badri S, Vibhakar S, et al. Early development of non- Hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients-implications for immune reconstitution. AIDS Res Ther 2010;7:44.
101. Demopoulos BP, Vamvakas E, Ehrlich JE, et al. Non-acquired immunodeficiency syndrome-defining malignancies in patients infected with human immunodeficiency virus. Arch Pathol Lab Med 2003; 127:589-92.
102. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: Associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005;97:425-32.
103. Shiels MS, Cole SR, Kirk GD, et al. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 2009;52:611-22.
104. Frisch M, Biggar RJ, Engels EA, et al. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001;285:1736-45.
105. Engels EA. Inflammation in the development of lung cancer: epidemiological evidence. Expert Rev Anticancer Ther 2008;8:605-15.
106. Huang L, Schnapp LM, Gruden JF, et al. Presentation of AIDSrelated pulmonary Kaposi's sarcoma diagnosed by bronchoscopy. Am J Respir Crit Care Med 1996;153:1385-90.
107. Khalil AM, Carette MF, Cadranel JL, et al. Intrathoracic Kaposi's sarcoma. CT findings. Chest 1995;108:1622-6.
108. Godoy MC, Rouse H, Brown JA, et al. Imaging features of pulmonary Kaposi sarcoma-associated immune reconstitution syndrome. AJR Am J Roentgenol 2007;189:956-65.
109. Hamm PG, Judson MA, Aranda CP. Diagnosis of pulmonary Kaposi's sarcoma with fiberoptic bronchoscopy and endobronchial biopsy. A report of five cases. Cancer 1987;59:807-10.
110. Eisner MD, Kaplan LD, Herndier B, et al. The pulmonary manifestations of AIDS-related non-Hodgkin's lymphoma. Chest 1996;110: 729-36.
111. Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med 2010;153: 452-60.
112. Brock MV, Hooker CM, Engels EA, et al. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr 2006;43: 47-55.
113. Suneja G, Shiels MS, Melville SK, et al. Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals. AIDS 2013;27:459-68.
114. Cadranel JL, Kammoun S, Chevret S, et al. Results of chemotherapy in 30 AIDS patients with symptomatic pulmonary Kaposi's sarcoma. Thorax 1994;49:958-60.
115. Kirova YM, Belembaogo E, Frikha H, et al. Radiotherapy in the management of epidemic Kaposi's sarcoma: A retrospective study of 643 cases. Radiother Oncol 1998;46:19-22.
116. Hannon FB, Easterbrook PJ, Padley S, et al. Bronchopulmonary Kaposi's sarcoma in 106 HIV-1 infected patients. Int J STD AIDS 1998;9:518-25.
117. Re A, Michieli M, Casari S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood 2009;114:1306-13.
118. Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol 2011;12: 905-12.